-
2022-500237-92-00
5
2021-04-23
Newly-diagnosed high-intermediate and high-risk diffuse large B-cell l
-
2023-503568-18-00
5
2021-04-13
Early human epidermal growth factor receptor 2 (HER2) positive breast
-
2024-514467-26-00
4
2021-04-07
Indolent Systemic Mastocytosis
-
2024-511637-35-00
5
2021-03-23
Elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL)
-
2023-507890-17-00
5
2021-02-22
Anemia associated with myeloproliferative neoplasm (MPN)-associated my
-
2024-516797-29-00
4
2021-01-12
locally advanced basal cell carcinoma
-
2023-507263-19-00
5
2020-12-23
Advanced Non-Small Cell Lung Cancer
-
2024-513616-95-00
10
2020-12-22
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
-
2023-504830-23-00
5
2020-12-16
B-cell Lymphoma
-
2024-513296-41-00
4
2020-12-03
Colorectal cancer spread at distance, RAS BRAF wild type pretreatted
-
2023-509358-72-00
5
2020-11-23
Diffuse large B-cell lymphoma
-
2023-504828-25-00
9
2020-11-16
Chronic Lymphocytic Leukemia
-
2024-513422-38-00
5
2020-09-28
Newly diagnosed multiple myeloma
-
2024-515953-52-00
5
2020-07-24
Post-Essential Thrombocythaemia Myelofibrosis
-
2023-509908-15-00
10
2020-01-20
Mantle Cell Lymphoma
-
2024-514197-50-00
9
2020-01-17
CD123 positive Acute Myeloid Leukemia
-
2024-511747-25-00
4
2019-12-23
B-cell non-Hodgkin lymphoma (NHL)
-
2024-510626-89-00
5
2019-11-18
Non-Alcoholic Steatohepatitis (NASH)
-
2024-510776-20-00
5
2019-10-25
Female or male patients with histologically confirmed HR-positive, HER
-
2023-505321-14-00
10
2019-09-06
Warm Autoimmune Hemolytic Anemia
-
2023-505810-12-00
5
2019-09-03
Lower limb spasticity
-
2024-511641-18-00
4
2019-08-01
Diffuse Large B-cell Lymphoma ABC
-
2023-506153-38-00
5
2019-07-11
High-risk localized or locally advanced prostate cancer
-
2023-506733-30-00
4
2019-05-16
Multiple Myeloma relapsed and/or refractory